Home > Publications Database > CSF Beta-Synuclein, SNAP-25, and Neurogranin in Infectious and Autoimmune Inflammatory Neurologic Diseases. > print

001     281642
005     20251103102758.0
024 7 _ |a 10.1212/NXI.0000000000200491
|2 doi
024 7 _ |a pmid:41061183
|2 pmid
037 _ _ |a DZNE-2025-01160
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Abu-Rumeileh, Samir
|0 0000-0003-0631-8506
|b 0
245 _ _ |a CSF Beta-Synuclein, SNAP-25, and Neurogranin in Infectious and Autoimmune Inflammatory Neurologic Diseases.
260 _ _ |a Philadelphia, Pa.
|c 2025
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762161596_20025
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Beta-synuclein (beta-syn), synaptosomal-associated protein 25 (SNAP-25), and neurogranin are CSF biomarkers of synaptic damage, which have been poorly investigated in non-neurodegenerative neurologic diseases. In this study, we examined the diagnostic and prognostic role of these markers compared with the neuroaxonal damage marker neurofilament light chain protein (NfL) in infectious and autoimmune inflammatory neurologic diseases (IINDs and AINDs).This cohort study included CSF samples from patients with different etiologies of IIND (varicella-zoster virus, herpes simplex virus, tick-borne meningoencephalitis, bacterial meningitis/(meningo)encephalitis, neuroborreliosis, or other/unknown etiology) or AIND (autoimmune encephalitis or other etiology) as well as controls.A total of 123 patients with IINDs (mean age 55.23 ± 18.04 years, 43.2% female), 22 with AINDs (age 60.41 ± 16.03 years, 81.8% female), and 95 controls (age 52.39 ± 17.94 years, 56.9% female) were enrolled. Compared with the control group, participants with IINDs and AINDs showed higher concentrations of beta-syn (p < 0.001 and p = 0.038, respectively), neurogranin (p = 0.039 and p = 0.002, respectively), and NfL (p < 0.001 and p = 0.001, respectively), with no differences between the 2 latter groups. Overall, synaptic markers and NfL demonstrated poor-to-moderate diagnostic accuracy in discriminating between diagnostic groups (area under the curve 0.366-0.809). All synaptic biomarkers were elevated in participants with IINDs presenting with altered mental status (beta-syn, p < 0.001; SNAP-25, p = 0.002; and neurogranin, p = 0.008), seizures (beta-syn, p = 0.013; SNAP-25, p = 0.005; and neurogranin, p = 0.004), and inflammatory changes on neuroimaging (beta-syn, p = 0.016; SNAP-25, p = 0.029; and neurogranin, p = 0.007). Participants with AINDs requiring intensive care showed higher levels of beta-syn (p = 0.033) and NfL (p = 0.002). Participants with IINDs with a poor functional status (modified Rankin Scale [mRS] scores of 3-6) exhibited higher concentrations of beta-syn (p < 0.001), SNAP-25 (p = 0.022), neurogranin (p = 0.004), and NfL (p < 0.001) compared with those with mRS scores of 0-2. Accordingly, higher levels of synaptic markers were associated with poorer short-term outcomes in patients with IINDs, but not in those with AINDs.Elevated CSF levels of beta-syn, neurogranin, and NfL may suggest a common pattern of synaptic and neuroaxonal damage in both IINDs and AINDs. Although these biomarkers have limited value in distinguishing between different diseases, they are associated with clinical severity and with short-term outcome, particularly in patients with IINDs.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Neurogranin
|0 132654-77-4
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Synaptosomal-Associated Protein 25
|2 NLM Chemicals
650 _ 7 |a SNAP25 protein, human
|2 NLM Chemicals
650 _ 7 |a SNCA protein, human
|2 NLM Chemicals
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neurogranin: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Synaptosomal-Associated Protein 25: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Autoimmune Diseases of the Nervous System: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Autoimmune Diseases of the Nervous System: diagnosis
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: diagnosis
|2 MeSH
650 _ 2 |a alpha-Synuclein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Encephalitis: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Encephalitis: diagnosis
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
700 1 _ |a Erhart, Deborah K
|b 1
700 1 _ |a Barba, Lorenzo
|0 0000-0003-1328-3620
|b 2
700 1 _ |a Konen, Franz Felix
|0 0000-0002-8609-5674
|b 3
700 1 _ |a Stapf, Caroline
|b 4
700 1 _ |a Senel, Makbule
|0 0000-0002-2737-7495
|b 5
700 1 _ |a Hudasch, Dominica
|0 0000-0002-1402-5415
|b 6
700 1 _ |a Steinacker, Petra
|0 0000-0001-6697-6522
|b 7
700 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 8
|u dzne
700 1 _ |a Weise, Christopher M
|b 9
700 1 _ |a Ticozzi, Nicola
|0 0000-0001-5963-7426
|b 10
700 1 _ |a Halbgebauer, Steffen
|0 P:(DE-2719)9002026
|b 11
700 1 _ |a Verde, Federico
|0 0000-0002-3977-6995
|b 12
700 1 _ |a Sühs, Kurt-Wolfram
|0 0000-0002-8077-481X
|b 13
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 14
|u dzne
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 15
773 _ _ |a 10.1212/NXI.0000000000200491
|g Vol. 12, no. 6, p. e200491
|0 PERI:(DE-600)2767740-0
|n 6
|p e200491
|t Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
|v 12
|y 2025
|x 2332-7812
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281642/files/DZNE-2025-01160.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281642/files/DZNE-2025-01160.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281642
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9001560
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9002026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)9002007
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-13T18:57:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-13T18:57:06Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-02-13T18:57:06Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROL-NEUROIMMUNOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000073
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21